ganitumab
mAbexperimental
Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (IGF1R), designed for the treatment of cancers. — Wikipedia
Clinical trial activity
30 trials · 24 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
23
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2005 (NCT00562380)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoid Tumor · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Dermatology · Phase 2
- Endocrine Gland Neoplasms · Phase 3
- Gastrointestinal Neoplasms · Phase 1/Phase 2
- Hemangiosarcoma · Phase 2
- Intestinal Neoplasms · Phase 1
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 2
- Melanoma · Phase 2
- Neoplasm Metastasis · Phase 3
- Neoplasms · Phase 3
- Neuroectodermal Tumors · Phase 3
- Neuroendocrine Tumors · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 3
- Prostatic Neoplasms · Phase 1
- Rectal Neoplasms · Phase 1/Phase 2
- Rhabdomyosarcoma · Phase 1/Phase 2
- Rhabdomyosarcoma, Alveolar · Phase 1/Phase 2
- Rhabdomyosarcoma, Embryonal · Phase 1/Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 3
- Small Cell Lung Carcinoma · Phase 1/Phase 2
Mechanism of action
- Insulin-like growth factor I receptorANTAGONIST
IGF1R antagonist
Inhibits the high-affinity binding of IGF-I and IGF-II to IGF-IR preventing the subsequent triggering of the PI3K/Akt signaling pathway.
IGF1R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGanitumab ↗
- ChEMBLCHEMBL1743024 ↗
Also known as
- amg 479
- amg 479
- amg-479
- ganitumab
- ganitumab
- ganitumab
- ganitumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04199026 | Early Phase 1 (Phase 1) | Jan 31, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT04129151 | Phase 2 | Nov 30, 2019 | 1 Million 4 Anna Foundation, Carson Sarcoma Foundation, ChemoWarrior: the eli sidler foundation, Harvard University, i-ROK Foundation, Rutledge Cancer Foundation |
| NCT03041701 | Phase 1/Phase 2 (Phase 2) | Jul 4, 2017 | National Cancer Institute (NCI) |
| NCT03029481 | N/A | Jan 20, 2017 | NantCell, Inc., University of California, Los Angeles |
| NCT02306161 | Phase 3 | Dec 8, 2014 | National Cancer Institute (NCI) |
| NCT01708161 | Phase 1/Phase 2 (Phase 2) | Nov 27, 2012 | NantCell, Inc., Novartis |
| NCT01479179 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2012 | Amgen, University of Texas at Houston |
| NCT01562899 | Phase 2 | Aug 1, 2012 | Array BioPharma |
| NCT01473303 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2012 | Harvard University, National Cancer Institute (NCI) |
| NCT01318642 | Phase 2 | May 1, 2012 | Amgen |
| NCT01298401 | Phase 1 | Feb 1, 2012 | National Cancer Institute (NCI), NRG Oncology, Radiation Therapy Oncology Group, University of Texas at Houston |
| NCT01231347 | Phase 3 | Apr 1, 2011 | Amgen, NantCell, Inc., Takeda |
| NCT01327612 | Phase 2 | Mar 1, 2011 | Amgen |
| NCT01122199 | Phase 1 | May 14, 2010 | Amgen, Big Ten Cancer Research Consortium, Indiana University, Novartis |
| NCT01061788 | Phase 1 | Apr 1, 2010 | Duke University, NantCell, Inc., Novartis |
| NCT01042379 | Phase 2 | Mar 1, 2010 | QuantumLeap Healthcare Collaborative, University of California, San Francisco |
| NCT01024387 | Phase 2 | Mar 1, 2010 | Amgen, Harvard University, University of South Florida |
| NCT00891930 | Phase 2 | May 1, 2009 | Amgen |
| NCT00813605 | Phase 2 | Mar 1, 2009 | Amgen, NantCell, Inc. |
| NCT00719212 | Phase 2 | Jan 1, 2009 | Translational Research in Oncology, University of California, Los Angeles |
Showing 20 of 30 trials
Page 1 / 2
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 17 | 5 | 3 | 2005 |
| NantCell, Inc. | For profit | 12 | 9 | 4 | 2006 |
| National Cancer Institute (NCI) | Government | 6 | 3 | 3 | 2005 |
| Harvard University | Academic/Hospital | 3 | 2 | 1 | 2010 |
| Novartis | For profit | 3 | 1 | 2 | 2010 |
| University of California, Los Angeles | Academic/Hospital | 3 | 1 | 2 | 2009 |
| University of Texas at Houston | Academic/Hospital | 3 | 2 | 2 | 2012 |
| Translational Research in Oncology | Academic/Hospital | 2 | 2 | 1 | 2009 |
| 1 Million 4 Anna Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Array BioPharma | For profit | 1 | 1 | 1 | 2012 |
| Big Ten Cancer Research Consortium | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Carson Sarcoma Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
| ChemoWarrior: the eli sidler foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| i-ROK Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2012 |
| QuantumLeap Healthcare Collaborative | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Radiation Therapy Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Rutledge Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
24 organizations
Page 1 / 2